Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06889584 · ClinicalTrials.gov registry record · NA
Supplement Combination on Stress and Sleep
A NA study, sponsored by University of South Carolina.
- Completed
- Registry status
- NA
- Development phase
- 115
- Enrollment target
NCT06889584: Completed NA study, sponsored by University of South Carolina.
NCT06889584 is a NA study that has completed, run by University of South Carolina. The registered enrollment target is 115 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06889584, a NA study, has completed, sponsored by University of South Carolina.
- COMPLETED
- Registry status
- NA
- Development phase
- 115 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to assess the effects of a supplement combination on measures of sleep quality and stress in healthy adults.
Primary Outcome
To determine changes in perceived stress by way of the Cohen's Perceived Stress scale. The minimum is 0 and max is 40, with higher values meaning more stress.
Interventions
- COMBINATION_PRODUCT All Active Supplement Combinations (Ashwagandha, Rhodiola rosea, magnesium threonate, L-theanine, and apigenin))
- COMBINATION_PRODUCT AM Active Supplement Combination (Ashwagandha and Rhodiola rosea)
- COMBINATION_PRODUCT PM Active Supplement Combination (Magnesium threonate, L-theanine, and apigenin)
- OTHER AM and PM Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2025-02-15 |
| Est. Completion | 2026-02-01 |
| Phase | NA |
What the finished NCT06889584 record still lists
NCT06889584 is an interventional study that assigns participants to a tested intervention. The registered 115 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 4 interventions - of which All Active Supplement Combinations (Ashwagandha, Rhodiola rosea, magnesium threonate, L-theanine, and apigenin)) is the first listed.
NCT06889584 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06889584 about?
NCT06889584 is a clinical study titled "Supplement Combination on Stress and Sleep". The purpose of this clinical trial is to assess the effects of a supplement combination on measures of sleep quality and stress in healthy adults.
What is the current status of trial NCT06889584?
This trial is currently completed. It is a NA study. The enrollment target is 115 participants. The study started on 2025-02-15. Estimated completion is 2026-02-01.
What interventions are being tested in trial NCT06889584?
The interventions under investigation include: All Active Supplement Combinations (Ashwagandha, Rhodiola rosea, magnesium threonate, L-theanine, and apigenin)) (COMBINATION_PRODUCT), AM Active Supplement Combination (Ashwagandha and Rhodiola rosea) (COMBINATION_PRODUCT), PM Active Supplement Combination (Magnesium threonate, L-theanine, and apigenin) (COMBINATION_PRODUCT), AM and PM Placebo (OTHER).
Who is sponsoring clinical trial NCT06889584?
This trial is sponsored by University of South Carolina, which has 157 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06889584's enrollment target sits among peer trials
115 810th of 2000 higher than 1,190 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02346929 · 115 participants · NA
Hematoma Block for Distal Radius Fracture
- NCT03394365 · 115 participants · Phase 3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- NCT03907475 · 115 participants · Phase 2
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
- NCT05086692 · 115 participants · Phase 1
A Beta-only IL-2 ImmunoTherapY Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI